NCT00280150View on ClinicalTrials.gov

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2013

Conditions
Lung Cancer
Interventions
BIOLOGICAL

bevacizumab

Given IV

DRUG

carboplatin

Given IV

DRUG

erlotinib hydrochloride

Given orally

DRUG

paclitaxel

Given IV

RADIATION

3-dimensional conformal radiation therapy

Given 5 days a week for 7 weeks

Trial Locations (3)

28025

Batte Cancer Center at Northeast Medical Center, Concord

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER